Healthcare Industry News: OXINIUM
News Release - February 27, 2009
Smith & Nephew Introduces Metal Liner Option for the Modular R3(TM) Acetabular Cup SystemMEMPHIS, Tenn., Feb. 27 (Healthcare Sales & Marketing Network) -- Smith & Nephew, Inc. (NYSE: SNN, LSE: SN) Orthopaedic Reconstruction & Trauma today announced the introduction of a metal liner option for its R3 Acetabular System, an advanced multi-bearing acetabular cup system used in hip replacement and resurfacing procedures.
The metal liner was recently approved by the Food and Drug Administration for use with the BIRMINGHAM HIP(TM) Resurfacing (BHR(TM)) System. Since March 2008, the R3 system has been fitted with cross-linked polyethylene (XLPE) liners for use in total hip replacement cases, and Smith & Nephew this week received FDA approval of its ceramic liner option. It is the only acetabular system available to surgeons that accommodates the major advanced bearing options, including metal-on-metal, ceramic-on-ceramic, cobalt chrome on cross- linked polyethylene (XLPE), and the company's exclusive OXINIUM(TM) Oxidized Zirconium on XLPE.
The multi-bearing cup, in addition to providing intraoperative flexibility for surgeons, provides solutions designed to reduce wear and the subsequent need for revision surgery. Its range of inserts accommodates larger head sizes and is optimized to help the R3 system achieve joint stability and a greater range of motion. By utilizing disposable trial liners and a single set of instruments for all bearings, the R3 Acetabular System gives surgeons simplicity in the operating room and confidence in a stable, multi-bearing system.
"The R3 system reaffirms our reputation as the leading innovator in orthopaedics," says Joseph DeVivo, president of Smith & Nephew Orthopaedics. "Not only have we enhanced our customers' ability to make bearing surface decisions intraoperatively, but we've expanded our BHR hip portfolio to include a simple, modular cup system. This reinforces our strategy to partner with healthcare professionals to help patients reclaim their active lives."
In tests, the R3 Acetabular System's proprietary STIKTITE(TM) porous coating demonstrated a higher coefficient of friction than trabecular metal on both cancellous and cortical bone, indicating the potential for superior scratch-fit feel and initial fixation. Additionally, the R3 system is enhanced by a proprietary hard-bearing alignment guide -- a thin plastic shield resembling a disposable coffee cup lid that enables surgeons to simply and accurately place a ceramic or metal liner into the shell during surgery. This straightforward technique reduces the risk of improper seating and malalignment seen in other systems.
About Smith & Nephew
Smith & Nephew is a global medical technology business, specialising in Orthopaedics, including Reconstruction, Trauma and Clinical Therapies; Endoscopy and Advanced Wound Management. Smith & Nephew is a global leader in arthroscopy and advanced wound management and is one of the leading global orthopaedics companies.
Smith & Nephew is dedicated to helping improve people's lives. The Company prides itself on the strength of its relationships with its surgeons and professional healthcare customers, with whom its name is synonymous with high standards of performance, innovation and trust. The Company operates in 32 countries around the world. Annual sales in 2008 were $3.8 billion.
This press release contains certain "forward-looking statements" within the meaning of the US Private Securities Litigation Reform Act of 1995. In particular, statements regarding planned growth in our business and in our trading margins discussed under "Outlook" are forward-looking statements as are discussions of our product pipeline. These statements, as well as the phrases "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions, are generally intended to identify forward-looking statements. Such forward- looking statements involve known and unknown risks, uncertainties and other important factors (including, but not limited to, the outcome of litigation and regulatory approvals) that could cause the actual results, performance or achievements of Smith & Nephew, or industry results, to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20F, for a discussion of certain of these factors.
All forward-looking statements in this press release are based on information available to Smith & Nephew as of the date hereof. All written or oral forward-looking statements attributable to Smith & Nephew or any person acting on behalf of Smith & Nephew are expressly qualified in their entirety by the foregoing. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement contained herein to reflect any change in Smith & Nephew's expectation with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.
Source: Smith & Nephew
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsSmith & Nephew launches NOVOSTITCH(TM) PRO Meniscal Repair System in Europe
Smith & Nephew Launches ARIA Care Management Platform for Patients and Providers
Smith & Nephew announces new milestone with its OXINIUM(TM) Advanced Bearing System implants surpassing two million procedures